Chronic Lyme vs. Post-Treatment Lyme Disease Syndrome: What the Research Actually Says

If you've spent any time in Lyme disease communities, you've probably noticed that even naming the condition is contested. Is it "chronic Lyme disease"? "Post-treatment Lyme disease syndrome" (PTLDS)? "Persistent Lyme"? The label a patient gets often has less to do with their symptoms and more to do with which doctor they happened to see — and that says something important about where the science actually stands.

This isn't a fringe disagreement. It's a real, active scientific controversy, and patients are the ones caught in the middle of it — often while feeling dismissed by the very system meant to help them. So let's walk through what's actually being debated, what the newest research shows, and why "it's probably just anxiety" was never a good enough answer.

The Two Camps, Explained

For decades, the Lyme disease field has been split into two loosely defined camps.

The mainstream position, represented largely by the Infectious Diseases Society of America (IDSA), holds that Lyme disease — caused by the bacterium Borrelia burgdorferi — is reliably cured with a standard 2- to 4-week course of antibiotics. In this view, if symptoms like fatigue, joint pain, and brain fog persist for six months or more after treatment, that's PTLDS: a real, recognized condition, but one attributed to lingering immune dysfunction or inflammation rather than ongoing infection. Extended antibiotics, in this framework, aren't expected to help, because there's presumed to be no active bacteria left to kill.

The other camp, represented by groups like the International Lyme and Associated Diseases Society (ILADS), argues that in at least some patients, Borrelia can survive standard treatment — persisting in a dormant or hard-to-detect form — and that ongoing symptoms may reflect a genuine, unresolved infection. This is the basis for the term "chronic Lyme disease," and it's the rationale some clinicians use for longer or repeated courses of antibiotics.

Neither position is a straw man. Both have real researchers and real clinical experience behind them. And crucially, both are trying to explain the same thing: a meaningful subset of Lyme patients — roughly 10 to 20% of those who receive standard treatment — don't get fully better.

Why the Divide Persists

Part of the reason this debate hasn't been resolved is that the tools we use to diagnose and study Lyme disease are genuinely inadequate.

Testing is a mess. The standard two-tier test (an ELISA followed by a Western blot) doesn't detect the bacterium itself — it detects antibodies your immune system made in response to it. That creates two big problems. First, antibodies typically don't become reliably detectable until three to four weeks after infection, so someone tested early in the illness can have a real infection and still test negative — standard two-tier testing may catch only 30–40% of cases in the first few weeks. Second, because the test measures immune memory rather than active infection, it can't reliably tell you whether an infection is ongoing or already resolved. That means the very test used to gatekeep a Lyme diagnosis — and to gatekeep whether a patient's ongoing symptoms are taken seriously — is at its weakest exactly when clarity matters most.

This is a big deal for the chronic Lyme/PTLDS debate specifically, because it means "your test is negative" doesn't actually settle the question of whether someone was ever properly diagnosed, or whether an early, missed infection could explain symptoms that show up later.

PTLDS itself is a fuzzy category. Researchers studying "post-treatment Lyme disease and other infection-associated chronic illnesses" — a category that also includes long COVID and ME/CFS — have pointed out that the field has struggled with inconsistent patient selection, a lack of standardized protocols, and control groups that don't always have solid proof the initial infection was really Lyme. In plain terms: a lot of the research trying to settle this debate has been built on shaky foundations, which is part of why both sides can point to studies that seem to support their view.

What the Newest Science Suggests

This is where it gets genuinely interesting — because recent research is starting to offer a more nuanced answer than either camp's original framing.

In 2025, a team at Northwestern University led by microbiologist Brandon Jutras published findings that may reshape how we think about PTLDS entirely. They found that when Borrelia bacteria die off during treatment, fragments of their cell wall — a molecule called peptidoglycan — don't necessarily clear from the body right away. Tracking how peptidoglycan from different bacteria moves through the body, the researchers found that while most bacterial cell wall material is shed quickly, Lyme's peptidoglycan can linger for weeks to months, tending to pool in places like the liver and joint fluid.

That distinction matters enormously. It suggests a genuine biological explanation for persistent symptoms that is neither "you still have an active infection that needs more antibiotics" nor "it's all in your immune system's overreaction with no physical trigger." Instead, it points to a third possibility: the body may keep responding to leftover debris from a bacterium that's already dead. As Jutras put it in discussing the parallel with another contested post-infectious illness, Lyme and long COVID are very different diseases, but they may share a broader pattern of harmful inflammation triggered by remnants of a past infection rather than an infection that's still active.

This finding, paired with a related 2025 study identifying an existing beta-lactam antibiotic that specifically targets Lyme bacteria in mice, has real implications for patients: it opens the door to treatments aimed at clearing that lingering debris or calming the immune response to it — rather than the current all-or-nothing choice between "no more treatment" and "months of antibiotics."

Other research is approaching the persistence question from a different angle entirely, looking at whether Borrelia can enter a dormant, drug-tolerant state — sometimes called a "persister" form — that could evade standard antibiotic courses in lab and animal models. This work doesn't prove that persister bacteria explain chronic symptoms in humans, but it does mean the ILADS camp's core intuition — that bacterial survival is biologically plausible — isn't unreasonable on its face, even if it hasn't been confirmed as the driver of most cases.

The Hard Part: What About Long-Term Antibiotics?

Here's where a patient-advocate lens has to stay honest about the evidence, because this is the part of the debate with real safety stakes.

Multiple randomized controlled trials — including the well-designed PLEASE study in Europe — have tested whether extended antibiotic courses actually improve persistent symptoms compared to placebo. The consistent finding across this line of research is that longer courses generally haven't shown a meaningful benefit over shorter ones or over placebo for most patients with persistent symptoms. Similarly, more recent European trials on active neuroborreliosis found that six weeks of doxycycline was no more effective than two weeks.

And prolonged antibiotics, especially IV regimens, are not risk-free. Claims-data analysis of a large insured PTLDS patient population found that patients who received IV antibiotic treatment had roughly eight times the 90-day hospitalization rate of those who didn't — 7.3% versus 0.9% — along with higher rates of new infections and electrolyte imbalances. Case series from the CDC have documented serious complications, including septic shock and bone infections, tied to long-term IV antibiotic use for chronic Lyme.

This doesn't mean patients pursuing longer treatment are being reckless or that clinicians offering it are acting in bad faith — many are responding to real suffering that the mainstream system has too often waved away. But it does mean that "just try it, what's the harm" isn't an accurate way to frame IV antibiotics specifically. Patients deserve to make that choice with full information about both the uncertain benefit and the documented risk, not to be either denied care entirely or handed a treatment without a clear picture of the trade-offs.

Where This Leaves Patients

If you're living with persistent symptoms after a Lyme diagnosis — or you suspect an undiagnosed case is behind symptoms that started after a summer of hiking, gardening, or time outdoors — a few things are worth holding onto:

• Your symptoms are real, and the science increasingly backs that up. The idea that persistent post-Lyme symptoms are "all psychological" is losing ground fast. Recent research on peptidoglycan persistence, immune-antigen responses, and biological plausibility for bacterial survival all point toward physical, identifiable mechanisms — even where the full picture isn't settled yet.

• A negative test doesn't necessarily mean you never had Lyme, especially if it was drawn early in illness. Testing limitations are a documented, acknowledged weakness in the field, not a fringe claim.

• The treatment debate is genuinely unresolved — and that's different from "nothing works." The disappointing trial results for long-term antibiotics don't mean nothing can help; they mean the field hasn't yet found the right target. Emerging research into peptidoglycan clearance, anti-inflammatory approaches, and more precisely targeted antibiotics may represent that next generation of options.

• It's reasonable to want a second opinion, and reasonable to ask hard questions about any treatment offered — including long courses of antibiotics — given the documented risks. Being your own advocate doesn't mean distrusting all of mainstream medicine; it means asking any clinician, from any camp, to walk you through the actual evidence for what they're recommending.

The chronic Lyme vs. PTLDS debate probably won't be fully resolved for years. But the newest research suggests the two camps may be describing different pieces of the same puzzle — one where lingering bacterial debris, immune overreaction, and possibly, in some cases, surviving bacteria all play a role depending on the patient. That's a more complicated answer than either side's origin story, but it's also a more hopeful one: it means the path forward isn't "believe camp A" or "believe camp B" — it's better science, better diagnostics, and treatments that actually target what's really going on in each patient's body.

This post is intended for general information and to reflect current research; it isn't a substitute for individualized medical advice. If you're navigating persistent symptoms after Lyme disease, a physician familiar with the latest research — including specialists in infectious disease or, where appropriate, Lyme-literate providers — can help you weigh your specific options.